Novartis Launches in Spain the First Therapy to Reduce Cholesterol

Cholesterol can become less of a problem. Leqvio, the new drug from Novartis, arrives in Spain with the approval of the Ministry of Health, becoming the first and only therapy to reduce cholesterol with two doses per year. 

In this way, the Swiss pharmaceutical company reaffirms its commitment to reimagine the approach to cardiovascular diseases to explore innovative access models and improve the lives of patients, according to the company statement.

In Spain, cardiovascular diseases are the leading cause of death; Specifically, they are responsible for one in four deaths. According to data from the National Institute of Statistics (INE), 119,196 people died in 2021 due to these diseases, 26.4% of the total deaths. In addition, cardiovascular diseases were also the first cause of hospitalization (12.9%) in 2021, with a total of 582,446 admissions to public hospitals.

Dr. Carlos Guijarro Herraiz, president of the Spanish Atherosclerosis Society (SEA), has highlighted that “the abandonment of chronic treatments with proven preventive efficacy is a serious problem in vascular disease.”

The manager added that “the availability of a powerful lipid-lowering treatment with sustained efficacy with only two administrations per year offers an extraordinary opportunity to promote adherence to treatment and, therefore, improve cardiovascular prognosis.”

Read more about Novartis and its latest drug against cholesterol, Leqvia, and find the most important financial news of the day with our companion app Born2Invest.

Novartis has acquired global rights to develop, manufacture, and commercialize Leqvio

Leqvio is approved for the treatment of primary hyperlipidemia as an adjunct to diet and statin therapy at the maximum tolerated dose to lower LDL-C. The drug is administered by subcutaneous injection with a starting dose, another dose after three months, and then a maintenance dose every six months. Leqvio is approved in more than 60 countries around the world, including the United States and the European Union.

Novartis has acquired global rights to develop, manufacture, and commercialize Leqvio under a licensing and collaboration agreement with Alnylam Pharmaceuticals, which is a leader in RNA interference-based therapies.

The Swiss pharmaceutical company Novartis obtained a net profit of $6,.37 million (€6 million) in the first nine months of 2023, which represents an increase of 16% compared to the profits recorded in the same period of the previous year, according to a company statement.

When discounting the effect of the spin-off of the generic subsidiary Sandoz, which was completed in October by Novartis, the multinational’s net profit until September increased by 25% annually, to $5.93 million (€5.9 million).

__

(Featured image by Myriams-Fotos via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.